Hosted on MSN35m
FiscalNote (NOTE) Q3 2024 Earnings Call Transcript
First and foremost, building on what I just noted regarding our emphasis on product, we will focus on delivering best-in-class product experiences ... other cutting-edge technologies and our data ...
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...